ReviewCell death & disease2026
Immune checkpoint inhibitor-related pneumonitis: current advances and the putative role of mesenchymal stem cell therapy.
Review in Cell death & disease, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
- Narrative review of the similarities and differences between immune checkpoint inhibitor- and antibody-drug conjugate-associated pneumonitis.Translational lung cancer research · 2026Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
9 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Immune checkpoint inhibitors (ICIs) are widely used in clinical oncology owing to their effectiveness against various tumors. However, by enhancing their immune responses, these inhibitors can trigger immune-related adverse events (irAEs) affecting various organ systems. Notably, pulmonary complications, particularly immune checkpoint inhibitor-related pneumonitis (ICIP), have emerged as one of the leading causes of treatment-related mortality in patients receiving ICIs. Given the limitations of current ICIP treatments, mesenchymal stem cells (MSCs) represent a promising therapeutic strategy owing to their immunomodulatory properties and ability to promote tissue repair. This article reviews recent advances in ICIP and proposes the potential applications of MSC therapy, emphasizing the need for further research into its efficacy and safety to improve ICIP management.
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.